MiNK Therapeutics announces presentation of iNKT cell therapy agenT-797 at ASGCT Annual Meeting, highlighting its adaptive immune modulation.
Quiver AI Summary
MiNK Therapeutics, Inc. has announced that an abstract on their investigational iNKT cell therapy, agenT-797, will be presented at the American Society of Gene and Cell Therapy Annual Meeting in May 2026. The presentation, led by Dr. Terese C. Hammond, will focus on the adaptive immune modulation exhibited by agenT-797 in cancer and acute respiratory distress syndrome (ARDS). MiNK Therapeutics is a clinical-stage biopharmaceutical company specializing in allogeneic iNKT cell therapies aimed at treating immune-mediated diseases and cancer. AgenT-797 is designed to enhance immune responses against difficult tumors and provide treatment options for conditions like graft-versus-host disease and severe pulmonary inflammation. Further details about the presentation will be released by ASGCT in mid-April.
Potential Positives
- Acceptance of an abstract for presentation at the prestigious ASGCT Annual Meeting highlights the scientific credibility and potential impact of MiNK Therapeutics' investigational therapy, agenT-797.
- The presentation of agenT-797 at a major conference can enhance visibility and attract interest from the biopharmaceutical community, investors, and collaborators.
- MiNK Therapeutics is developing a novel off-the-shelf iNKT cell therapy, which demonstrates innovation in addressing challenging treatment areas such as cancer and immune-mediated diseases.
Potential Negatives
- Despite the acceptance of the abstract for presentation, the press release does not provide substantial clinical data or results regarding the efficacy or safety of the agenT-797 therapy, which may raise concerns about the progress and readiness of the drug for market entry.
- The mention of forward-looking statements highlights that there are significant risks and uncertainties associated with the development of agenT-797, suggesting potential volatility in the company's future performance and investor confidence.
- The lack of detailed information on the upcoming poster presentation may indicate that the company is still in the early stages of research, which could reflect negatively on its competitive position in the biopharmaceutical market.
FAQ
What is agenT-797?
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy developed by MiNK Therapeutics for treating immune-mediated diseases and cancer.
When will agenT-797 be presented at ASGCT?
The abstract for agenT-797 will be presented at the ASGCT Annual Meeting from May 11-15, 2026, in Boston, MA.
Who is presenting the agenT-797 research?
Dr. Terese C. Hammond, Program Director at Kaweah Health Medical Center, will present the research on agenT-797.
What are the potential benefits of agenT-797?
AgenT-797 aims to enhance immune responses, improve tumor infiltration, and combat severe inflammation in critically ill patients.
Where can I find more information about MiNK Therapeutics?
More information about MiNK Therapeutics and their therapies can be found at www.minktherapeutics.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INKT Insider Trading Activity
$INKT insiders have traded $INKT stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $INKT stock by insiders over the last 6 months:
- BARBARA RYAN has made 0 purchases and 6 sales selling 2,000 shares for an estimated $27,477.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$INKT Hedge Fund Activity
We have seen 9 institutional investors add shares of $INKT stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 34,300 shares (+102.8%) to their portfolio in Q4 2025, for an estimated $382,445
- DRW SECURITIES, LLC added 25,677 shares (+inf%) to their portfolio in Q4 2025, for an estimated $286,298
- NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO added 7,755 shares (+40815.8%) to their portfolio in Q4 2025, for an estimated $86,468
- RENAISSANCE TECHNOLOGIES LLC removed 4,200 shares (-28.8%) from their portfolio in Q4 2025, for an estimated $46,830
- UBS GROUP AG added 3,900 shares (+69.1%) to their portfolio in Q4 2025, for an estimated $43,485
- GEODE CAPITAL MANAGEMENT, LLC added 1,441 shares (+11.3%) to their portfolio in Q4 2025, for an estimated $16,067
- TOWER RESEARCH CAPITAL LLC (TRC) removed 631 shares (-68.1%) from their portfolio in Q4 2025, for an estimated $7,035
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026, in Boston, MA.
Presentation Details:
- Abstract Title: AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS
- Presenter: Terese C. Hammond, MD; Program Director of Pulmonary and Critical Care, Kaweah Health Medical Center; Head of Inflammatory and Pulmonary Diseases, MiNK Therapeutics
Additional information on the poster presentation including session location and timing details will be made available by ASGCT via the ASGCT Annual Meeting conference program website in mid-April.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead candidate, agenT-797, is an off-the-shelf iNKT cell therapy currently in clinical development for GVHD, solid tumors, and severe pulmonary inflammation. With a scalable cryopreserved manufacturing process and differentiated biology bridging innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies. For more information, visit www.minktherapeutics.com or follow us on X @MiNK_iNKT.
About agenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as “master regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors. Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024 ) and to combat inflammation in critically ill patients with severe respiratory pathology ( Nature Communications . 2024).
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, and anticipated benefits of agenT-797; clinical trial design, timing, and enrollment; and MiNK’s broader development plans. These statements are subject to risks and uncertainties detailed in MiNK’s most recent filings with the Securities and Exchange Commission. MiNK cautions investors not to place undue reliance on these statements, which speak only as of the date of this release.
Contacts:
Investor Contact: 917-362-1370 |
[email protected]
Media Contact: 781-674-4428 |
[email protected]
Source : MiNK Therapeutics
